Very encouragingly, the first-in-class small molecule NT5C2 inhibitor CRCD2 was efficient against ALL tumor cells both in vitro and in vivo in mice, without detectable adverse effects (besides minimal weight loss) (16). The gene discussed is NT5C2; the disease is acute lymphoblastic leukemia.